Corcept Therapeutics Inc [CORT] stock is trading at $42.25, up 3.25%. An important factor to consider is whether the stock is rising or falling in short-term value. The CORT shares have gain 10.86% over the last week, with a monthly amount glided 22.71%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Corcept Therapeutics Inc [NASDAQ: CORT] stock has seen the most recent analyst activity on November 06, 2023, when Truist upgraded its rating to a Buy and also boosted its price target to $38 from $29. Previously, SVB Securities started tracking the stock with Market Perform rating on April 11, 2023, and set its price target to $25. On April 04, 2023, Piper Sandler initiated with a Overweight rating and assigned a price target of $27 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $22 on February 15, 2023. Truist downgraded its rating to a Hold but $30 remained the price target by the analyst firm on August 01, 2022. Jefferies upgraded its rating to Buy for this stock on July 27, 2022, and upped its price target to $35.
Corcept Therapeutics Inc [CORT] stock has fluctuated between $20.84 and $43.74 over the past year. Currently, Wall Street analysts expect the stock to reach $56.5 within the next 12 months. Corcept Therapeutics Inc [NASDAQ: CORT] shares were valued at $42.25 at the most recent close of the market. An investor can expect a potential return of 33.73% based on the average CORT price forecast.
Analyzing the CORT fundamentals
Corcept Therapeutics Inc [NASDAQ:CORT] reported sales of 569.61M for the trailing twelve months, which represents a growth of 39.15%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.22%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.22%. To continue investigating profitability, this company’s Return on Assets is posted at 0.18, Equity is 0.24 and Total Capital is 0.21. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 40.99 points at the first support level, and at 39.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 43.14, and for the 2nd resistance point, it is at 44.03.
Ratios To Look Out For
For context, Corcept Therapeutics Inc’s Current Ratio is 5.57. On the other hand, the Quick Ratio is 5.48, and the Cash Ratio is 1.28. Considering the valuation of this stock, the price to sales ratio is 7.75, the price to book ratio is 7.40 and price to earnings (TTM) ratio is 37.48.
Transactions by insiders
Recent insider trading involved Guyer William, Chief Development Officer, that happened on Sep 03 ’24 when 10000.0 shares were sold. Officer, Guyer William completed a deal on Sep 03 ’24 to buy 10000.0 shares. Meanwhile, Chief Business Officer Robb Gary Charles sold 3101.0 shares on Aug 26 ’24.
